Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

ImClone Leadership Battle Intensifies With Calls For Removal Of Six Directors

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Carl Icahn wants the chairman and interim CEO removed; CFO departs.

You may also be interested in...



Icahn Gets Wish With Departure Of ImClone’s Kies, But Will Door Open To Him?

Billionaire and his allies hold 40% of the biotech’s board, possibly leading to further changes.

Icahn Gets Wish With Departure Of ImClone’s Kies, But Will Door Open To Him?

Billionaire and his allies hold 40% of the biotech’s board, possibly leading to further changes.

Amgen Vectibix Approved For Metastatic Colorectal Cancer

The first entirely human anti-EGFR antibody will launch in early or mid-October.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS064949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By